Vaccine against measles, mumps and rubella live attenuated (Meals, mumps and rubella virus vaccine live attenuated)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceVaccine for the prevention of measles, rubella and mumpsVaccine for the prevention of measles, rubella and mumps
Dosage form: & nbsplyophilizate for the preparation of a solution for subcutaneous administration
Composition:

One vaccine dose of the vaccine (0.5 ml) contains:

- not less than 1000 tissue cytopathogenic doses (TCDs50) measles virus;

- not less than 5000 TCDs50 mumps virus;

- not less than 1000 TCDs50 the rubella virus;

- stabilizer-sorbitol - 5%, gelatin - 2.5%;

- Neomycin In sulphate - no more than 10 mcg.

Description:

Vaccine - homogeneous porous mass of yellowish white color, hygroscopic. The vaccine complies with WHO requirements.

Solvent - Clear, colorless liquid.

Pharmacotherapeutic group:MIBP vaccine
ATX: & nbsp

J.07.B.D.52   Measles virus in combination with mumps and rubella viruses - live attenuated

J.07.B.D   Vaccine for measles prevention

Pharmacodynamics:

The vaccine is a lyophilized mixture of liquid semi-finished vaccines against measles, mumps and rubella prepared by the method of separate cultivation of attenuated strains of measles virus (Edmonton-Zagreb) and rubella (Wistar RA 27/3) on human diploid cells, mumps virus (L-Zagreb) - on fibroblasts of chick embryos.

Indications:

Prevention of measles, mumps and rubella. In accordance with the National Calendar of preventive vaccinations, vaccination is carried out twice: after reaching 12 months of age and 6 years.

One-time immunization of susceptible girls and non-pregnant women is possible.

Contraindications:

- Acute infectious and non-infectious diseases, exacerbation of chronic diseases;

- immunodeficiency states, malignant blood diseases and neoplasms;

- a strong reaction (temperature rise above 40 ° C, hyperemia and / or edema of more than 8 cm in diameter at the site of vaccine administration) or complication of previous administration of measles, mumps and rubella vaccines;

- systemic allergic reactions to vaccine components (neomycin, chicken eggs, gelatin);

- pregnancy.

Note: HIV infection is not a contraindication to vaccination.

Dosing and Administration:

The vaccine must be dissolved only with the applied solvent at a rate of 0.5 ml per 1 dose with a sterile syringe and needle. Time of dissolution of the vaccine - no more than 3 minutes.

Dissolved drug is a clear, colorless or light yellow liquid.

Dissolved vaccine in a ten-dose packaging can be stored in a dark place at a temperature of 2 to 8 ° C for not more than 8 hours.

The vaccine dose of the drug (0.5 ml) must be injected deep into the shoulder region.

ATTENTION! The vaccine should only be administered subcutaneously.

As with all vaccines, due to the possibility of developing allergic reactions of immediate type, the vaccine should be monitored for at least 30 minutes. Vaccination sites should be provided with anti-shock therapy.

Side effects:

Most vaccines have a vaccine process that is asymptomatic.

At the site of administration of the vaccine, there may be short-term hyperemia, edema and denseness accompanied by pain.

A short-term rise in body temperature to 37.9 ° C may occur between 6 and 18 days after vaccine administration in no more than 8% of vaccinated patients and may be accompanied by malaise, headache, catarrhal phenomena and nausea; 1-2% of those vaccinated on day 6-14 after vaccination may have a short-term (on average 2 days) uneventful rash.

In rare cases, there may be a slight increase in parotid and other salivary glands, lymphadenopathy (an increase in predominantly occipital and posterior lymph nodes).

Reactions from the central nervous system are extremely rare.

In adolescents and adults, in rare cases, the development of arthralgias and arthritis is possible.

Interaction:

The vaccine can be administered simultaneously (on the same day) with other vaccines of the National calendar of preventive vaccinations or not earlier than 1 month after the previous vaccination. In this case, the drugs are injected with separate syringes into different parts of the body.

Tuberculin sample is recommended to be performed before or 4-6 weeks after vaccination.

After the administration of human blood products (immunoglobulins, plasma, etc.), the vaccine against measles, mumps and rubella should be administered no earlier than 3 months. After immunization with the measles, mumps and rubella vaccine, blood preparations should be administered no earlier than 2 weeks later. If it is necessary to use them before this time, vaccination should be repeated after 3 months.

Special instructions:

Edit Warnings

Before vaccination, the history of the vaccine should be studied, paying attention to the previous administration of the vaccines that make up the associated preparation, and the resulting occurrence of adverse reactions, and to conduct an examination.

Women of childbearing age should be warned about the need to take contraceptive measures within 3 months after vaccination.

Vaccinations are conducted:

- after acute infectious and non-infectious diseases, after exacerbation of chronic diseases - not earlier than 1 month after recovery;

- Pin non-severe forms of acute respiratory viral infection, acute intestinal diseases, etc. - immediately after the normalization of temperature;

- PAfter conducting immunosuppressive therapy - 12 months after the end of treatment.

Vaccination is not recommended in the period of rising incidence of serous meningitis.

Form release / dosage:Lyophilizate for the preparation of a solution for subcutaneous administration, 1 dose and 10 doses (complete with a solvent).
Packaging:

Vaccine - 1 or 10 doses in a vial of dark glass.

50 vials of vaccine for 1 dose or 10 doses together with 5 copies of instructions for use - in a cardboard box.

Solvent - 0.5 ml (per dose of vaccine) or 5.0 ml (per 10 doses of vaccine) - in an ampoule of colorless clear glass.

50 ampoules of solvent with 0.5 ml or 5.0 ml - in a cardboard box.

Storage conditions:

The vaccine is stored in a dark place out of the reach of children at a temperature of 2 to 8 ° C.

The solvent is stored at a temperature of 5 to 30 ° C. Do not freeze the solvent.

The vaccine is transported at a temperature of 2 to 8 ° C, the solvent at a temperature of 5 to 30 ° C.

Shelf life:

Shelf life of the vaccine is 2 years; solvent - 5 years.

The drug with expired shelf life is not subject to application.

Terms of leave from pharmacies:For hospitals
Registration number:П N013192 / 01
Date of registration:09.02.2009 / 04.04.2013
Expiration Date:Unlimited
The owner of the registration certificate: Serum Institute of India, Ltd. Serum Institute of India, Ltd. India
Manufacturer: & nbsp
Representation: & nbspSerum Institute of India, Ltd.Serum Institute of India, Ltd.India
Information update date: & nbsp12.01.2017
Illustrated instructions
    Instructions
    Up